J&J in $1 billion deal to bolster prostate-cancer focus

[riky]

J&J in $1 billion deal to bolster prostate-cancer focus

By Ransdell Pierson (Reuters) - Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, to bolster J&J's role in the field after it acquired another experimental prostate-cancer treatment four years ago that has become a leading brand. J&J on Monday said Aragon's lead product, called ARN-509, has potential to help patients whose prostate cancer has not yet spread to other parts of the body, as well as patients whose cancer has spread. ...

Source: You are not allowed to view links. Register or Login